As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town.

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Despite high debt from the Horizon Therapeutics acquisition, Amgen shows growth potential through obesity drugs, biosimilars ... we can look at already approved products with growth potential.

This was made possible by 10 products posting double-digit ... Another risk to Amgen is the potential that the drugs in its pipeline may not commercially materialize as expected.

High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, stocks that pay dividends regularly can be great addition ...

A high-dose form of Novo’s obesity drug led to 20% weight loss over 72 weeks. Meanwhile, Atara got a complete response letter ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Amgen’s Imdylltra (tarlatamab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with small cell lung cancer (SCLC). The drug has been specifically ...